PROGRAM CHAIR
Brad Dickerson, MD, MMSc, FAAN
Director, Massachusetts General Hospital
Frontotemporal Disorders Unit
Professor of Neurology, Harvard Medical School
Boston, MA
FACULTY PRESENTER
Marc Agronin, MD
Chief Medical Officer, Frank C. and Lynn Scaduto MIND Institute and Behavioral Health
Miami Jewish Health
Miami, FL
PROGRAM OVERVIEW
This educational enduring program is designed to provide clinicians who manage patients with Alzheimer’s disease with up-to-date information on agitation in these patients, the impact of agitation on patient and caregiver quality of life, behavioral approaches to managing agitation, and new and investigational medical therapies.
TARGET AUDIENCE
This innovative and community-based educational activity is designed to meet the educational needs of primary care clinicians, geriatricians, psychiatrists, and neurologists as well as patients and caregivers concerning the identification of agitation associated with Alzheimer’s disease and appropriate management strategies.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the pathophysiology of agitation in Alzheimer’s disease (AD), including changes in neurotransmitter levels, eg, norepinephrine, serotonin, and dopamine
- Evaluate best practices in screening to identify AD-related agitation
- Describe the pharmacologic profile of and clinical data for current and emerging agents for the management of AD-related agitation
- Recognize the impact agitation has on patient/caregiver quality of life
- Identify opportunities for caregivers to manage agitation in patients with AD-associated agitation
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Brad Dickerson, MD | Dr. Dickerson discloses that he is a consultant for Acadia, Alector, Arkuda Therapeutics, Biogen, Eisai, Genentech, Lilly, and Merck. He receives royalties from Cambridge University Press, Elsevier, and Oxford University Press. |
| Marc Agronin, MD | Dr. Agronin discloses that he is a consultant for Eli Lilly, Otsuka, and Corium. He is on the Speakers Bureau for Otsuka. He has conducted research for Neurim, Cassava, Otsuka, Cerevel, Karuna, Suven, True Binding, Eisai, Biogen, and Alzheon. |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Debra Gordon, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager, for Med Learning Group, has nothing to disclose.
- Jacquelyn Sandfort, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: February 28, 2024
EXPIRATION DATE: February 28, 2025
Copyright ©2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
